Horizon Therapeutics (NASDAQ:HZNP) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Friday, BidAskClub reports.

HZNP has been the topic of a number of other research reports. Citigroup increased their target price on Martin Marietta Materials from $239.00 to $255.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Piper Jaffray Companies set a $195.00 target price on Cummins and gave the company a “buy” rating in a research report on Thursday, April 4th. BMO Capital Markets set a $13.00 target price on Vale and gave the company a “hold” rating in a research report on Thursday, April 4th. TheStreet lowered Worthington Industries from a “b-” rating to a “c+” rating in a research report on Monday, June 10th. Finally, Mizuho set a $27.00 price objective on Horizon Therapeutics and gave the company a “hold” rating in a research note on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating to the company’s stock. Horizon Therapeutics has an average rating of “Buy” and a consensus target price of $31.91.

Horizon Therapeutics stock opened at $24.41 on Friday. The company has a current ratio of 1.74, a quick ratio of 1.68 and a debt-to-equity ratio of 0.90. Horizon Therapeutics has a 12 month low of $16.56 and a 12 month high of $29.44. The stock has a 50 day moving average of $23.88. The stock has a market cap of $4.51 billion, a price-to-earnings ratio of 11.62, a PEG ratio of 1.41 and a beta of 1.03.

Horizon Therapeutics (NASDAQ:HZNP) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $0.30 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.10 by $0.20. Horizon Therapeutics had a return on equity of 33.57% and a net margin of 3.79%. The business had revenue of $280.00 million for the quarter, compared to analyst estimates of $238.35 million. During the same quarter in the prior year, the firm posted $0.03 EPS. The business’s quarterly revenue was up 25.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Horizon Therapeutics will post 1.62 earnings per share for the current fiscal year.

In other Horizon Therapeutics news, EVP Vikram Karnani sold 13,111 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $25.02, for a total value of $328,037.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jeff Kent sold 3,620 shares of the firm’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $24.64, for a total value of $89,196.80. The disclosure for this sale can be found here. 4.10% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp boosted its holdings in Horizon Therapeutics by 4.9% during the fourth quarter. Bank of New York Mellon Corp now owns 905,417 shares of the biopharmaceutical company’s stock worth $17,691,000 after purchasing an additional 42,271 shares during the last quarter. United Services Automobile Association boosted its holdings in Horizon Therapeutics by 10.6% during the fourth quarter. United Services Automobile Association now owns 28,282 shares of the biopharmaceutical company’s stock worth $553,000 after purchasing an additional 2,721 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Horizon Therapeutics by 11.4% during the fourth quarter. Principal Financial Group Inc. now owns 842,673 shares of the biopharmaceutical company’s stock worth $16,466,000 after purchasing an additional 86,058 shares during the last quarter. Jane Street Group LLC boosted its holdings in Horizon Therapeutics by 126.4% during the fourth quarter. Jane Street Group LLC now owns 29,887 shares of the biopharmaceutical company’s stock worth $584,000 after purchasing an additional 16,687 shares during the last quarter. Finally, Thrivent Financial for Lutherans purchased a new position in Horizon Therapeutics during the fourth quarter worth about $458,000. 89.10% of the stock is owned by institutional investors and hedge funds.

Horizon Therapeutics Company Profile

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Recommended Story: How to Calculate Compound Annual Growth Rate (CAGR)

Analyst Recommendations for Horizon Therapeutics (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.